Back to Journals » OncoTargets and Therapy » Volume 9

Association of polymorphisms in interleukin-8 gene with cancer risk: a meta-analysis of 22 case–control studies

Authors Zhang M, Fang T, Wang K, Mei H, Lv Z, Wang F, Cai Z, Liang C

Received 25 December 2015

Accepted for publication 1 April 2016

Published 22 June 2016 Volume 2016:9 Pages 3727—3737


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Professor Jianmin Xu

Meng Zhang,1–3,* Tingting Fang,1–3,* Kai Wang,1–3,* Hongbing Mei,3 Zhaojie Lv,3 Feng Wang,3 Zhiming Cai,3 Chaozhao Liang1,2

1Department of Urology, The First Affiliated Hospital of Anhui Medical University, 2Institute of Urology, Anhui Medical University, Hefei, Anhui, 3Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, People’s Republic of China

*These authors contributed equally to this work

Abstract: Interleukin-8 (IL-8) is a kind of chemokine that plays an important role in the development and progression of many human malignancies. Previous studies have uncovered that polymorphisms in IL-8 is associated with the risk of many cancer types, but the results were inconsistent and inconclusive. In the present study, we aimed to explore the roles of IL-8 polymorphisms (rs2227307, rs2227306, +678T/C, rs1126647, and +1633C/T) and cancer risk through a systematic review and meta-analysis. Potential source of heterogeneity was sought out through sensitivity analysis. Desirable data were extracted and registered into databases. Finally, a total of ten publications comprising of 22 case–control studies, including 4,259 cases and 7,006 controls were ultimately eligible for the meta-analysis. No significant association was uncovered for all the five polymorphisms and the overall cancer risk. However, in the stratification analysis by cancer type, a significantly decreased risk of hepatocellular carcinoma was identified for rs2227306 polymorphism (T vs C: odds ratio [OR] =0.721, 95% confidence interval [CI] =0.567–0.916, Pz=0.007; TT vs CC: OR =0.447, 95% CI =0.274–0.728, Pz=0.001; TT vs TC + CC: OR =0.480, 95% CI =0.304–0.760, Pz=0.002). In conclusion, our data shows that rs2227306 polymorphism plays a protective role in hepatocellular carcinoma risk. Future well-designed studies with a larger sample size are warranted to verify our findings.

Keywords: interleukin-8, polymorphisms, cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]